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SUMMARY 
Chronic myelogenous leukaemia (CML) is a myeloproliferative disorder that 
results from the neoplastic transformation of haematopoietic progenitor cells. It 
accounts for 15-20% of leukaemias in adults and occurs with an incidence of 1-2 
cases per 100 000 population, and the patients have a median survival period of 
3-4 years from diagnosis. 
Knowledge of normal haematopoiesis has increased the understanding of how 
specific perturbations may lead to the development of a transformed or malignant 
phenotype that is now clinically recognized as leukaemia. The discovery of 
oncogenes initiated a laboratory effort where the focus was to elucidate as yet 
undescribed oncogenes and to understand how single allele mutations could act 
dominantly in the "gain of function" ability to transform cells and cause tumours. 
These investigations obscured the existence of another set of genes which also 
appeared to be permissive of tumour formation. In contrast to the oncogenes, 
these genes behaved in a recessive manner so that "loss of function" as opposed 
to "gain of function", resulted in tumour formation. These genes therefore 
appeared to behave as tumour suppressor genes. 
The role of tumour suppressor genes is to prevent tissue overgrowth, nullify cells 
with damaged genomes, and metastasis. The structure and expression of the 
p53 gene is altered in about 25% of myeloid blast crisis of CML, whereas chronic 
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phase CML rarely has detectable p53 alterations, suggesting that mutations in 
the p53 gene might be involved in the evolution of some cases of blast crisis. 
Oncogenes are genes that have the ability to transform normal cells into cancer 
cells. Not all O-type cyclins are expressed in each tissue, suggesting that their 
function may be linked to the specific tissues in which they are expressed. 
Increased expression of cyclin 01 can playa critical role in tumour development 
and in maintenance of the malignant phenotype, thus over-expression of cyclin 
01 can produce complex effects on various cellular functions involved in growth 
control and cell cycle progression. 
Fluorescence in situ hybridization (FISH) allows the detection of numerical 
aberrations in interphase cell nuclei and provides a simple, fast and reliable 
means to assess genetic instability in cancer cells. 
Significant p53 loss of allele was detected in 6 out of 25 samples, indicating that 
the p53 tumour suppressor gene can be involved in the progression of CML from 
chronic phase to blastic phase. Cyclin 01 amplification was not detected in any 
of the samples investigated by FISH, indicating that cyclin 01 is not expressed in 
cells of the lymphoid and myeloid lineages. 
Keywords: chronic myelogenous leukaemia, p53, cyclin 01, fluorescence in 
situ hybridization 
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OPSOMMING 
Kroniese mielo"iede leukemie is 'n mieloproliferatiewe siekte wat ontstaan a.g.v. 
die neoplastiese transformasie van hematologiese voorloperselle. Dit 
verteenwoordig 15-20% van leukemiee in volwassenes, met 'n insidensie van 1-2 
gevalle per 100 000 bevolking. Die pasiente het 'n mediaan oorleweringsperiode 
van 3-4 jaar vanaf diagnose. 
Kennis van norma Ie hematopo"iese het groter beg rip meegebring aangaande hoe 
spesifieke afwykings kan lei tot die ontwikkeling van 'n getransformeerde of 
maligne fenotipe wat klinies herken word as leukemie. Met die ontdekking van 
onkogene is 'n laboratoriumpoging ge"lnisieer waar die fokus toegespits was om 
voorheen onomskryfde onkogene te verduideliklverklaar, en om te verstaan hoe 
enkel alleel mutasies dominant kon optree met 'n "funksietoename" vermoe, om 
selle te verander en tumore te veroorsaak. Hierdie ondersoeke het egter die 
bestaan verberg van 'n ander stel gene wat klaarblyklik ook tumorformasie laat 
plaasvind he!. In teenstelling met die onkogene, het hierdie gene egter resessief 
opgetree sodat "funksieverlies" en nie "funksietoename" nie, tumorformasie 
veroorsaak he!. Derhalwe het hierdie gene skynbaar opgetree as 
tumoronderdrukkende gene. 
Die rol van tumoronderdrukkende gene is om abnormale weefsel proliferasie, 
vernietiging van beskadigde genome, en metastase te voorkom. Di~ struktuur en 
uitdrukking van die p53 geen is verander in ongeveer 25% van mielo"lede 
blastselkrisisse, waar kroniese fase seide opspoorbare p53 veranderings toon, 
wat dui daarop dat die muteerde p53 geen waarskynlik betrokke is in die evolusie 
van blastselkrisisse. 
Onkogene is gene wat die vermoe het om normale selle te transformeer. Nie aile 
O-tipe sikliene word uitgedruk in aile weefseltipes nie, wat dui daarop dat hul 
funksie waarskynlik gekoppel kan word aan die spesifieke weefsel waarin hulle 
uitgedruk word. Die oormatige uitdrukking van siklien 01 kan 'n kritieke rol speel 
in tumorontwikkeling en die handhawing daarvan, derhalwe kan oormatige 
uitdrukking van siklien 01 komplekse gevolge veroorsaak wat betrokke is by 
groeibeheer en selsiklusprogressie. 
Fluoresensie in situ hibridisasie (FISH) maak dit moontlik om numeriese 
afwykings in interfase selkem op te spoor en is 'n eenvoudige, vinnige en 
betroubare manier om genetiese onstabiliteit in kanker selle te bepaal. 
Betekenisvolle p53 alleel verlies was gevind in 6 uit 25 monsters, wat aandui dat 
die p53 tumoronderdrukkende geen betrokke kan wees in die vooruitgang van 
kroniese fase na blastfase. Siklien 01 amplifikasie is nie gevind in enige 
monsters met die FISH ondersoek nie, wat aandui dat siklien 01 nie amplifikasie 
word in selle van die limforede en mielorede sellyne nie. 
Sleutelwoorde: kroniese mielorede leukemia, p53, siklien 01, flouresensie in 
situ hibridisasie 
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CHAPTER 1 
INTRODUCTION 
Chronic myelogenous leukaemia (CML) is a malignancy of the human 
haematopoietic stem cell characterised by a reciprocal translocation between 
chromosomes 9 and 22, termed the Philadelphia chromosome (Ph), resulting in 
the formation of a hybrid BCRfABL (Abelson breakpoint cluster region) gene on 
chromosome 22 (Kantarjian et aI., 1985; Rowley, 1990; De Klein et aI., 1982). 
In its chronic phase, CML is characterised by an abnormal, unregulated 
expansion of myeloid, erythroid and megakaryocytic progenitors in the marrow. 
One of the most obvious characteristics of CML is the expansion of myeloid 
progenitors and precursors, which mature relatively normally. Increases in cell 
number can be the result of decreased cell death, increased production of cells, 
or both (Daley et al., 1990). 
Although the Ph chromosome, which generates p210BCR/ABL, is an unique 
chromosomal abnormality in the chronic phase, additional chromosomal 
abnormalities are frequently detected in the blast crisis, suggesting that 
superimposed genetic events are responsible for disease progression (Honda et 
al.,2000) 
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The p53 gene has been mapped to the short arm of chromosome 17 and 
encodes a 53 kiloDalton (kD) nuclear phosphoprotein involved in the control of 
cell proliferation (Isobe et a/. , 1986; Lane and Benchimol , 1990). It plays a 
critical role in cellular proliferation and regulation of the cell cycle (Lane and 
Benchimol , 1990). It is frequently altered by mutations, rearrangements or 
deletions which contribute to the genesis or progression of a wide variety of 
human cancers (Cheng et a/. , 1992). Inactivation of the p53 gene has been 
demonstrated in human cancers, such as colorectal and lung cancers, and 
leukaemias (Sugimoto eta/. , 1992; Cheng eta/. , 1992). Loss or mutation of the 
tumour suppressor gene, p53, is one of the most frequent secondary mutations in 
CML blast crisis. The transition between chronic phase and blast crisis is 
associated with increased resistance to apoptosis correlating with poor prognosis 
(Di-Bacco et al., 2000). 
D-type cyclins are important cell cycle regulators that promote cellular 
proliferation in response to growth factors by inactivation of the retinoblastoma 
protein (RB). Cyclin D1 has been shown to be over-expressed in several cancer 
types and to act as an oncogene in breast cancers. Signal transducers and 
activators of transcription (STAT) are a family of transcription factors that were 
originally identified as mediators of cytokine-induced gene expression. STAT5 
also plays a major role in cellular transformation by the BCRlABL oncogene (De-
Groot et a/., 2000). As D-type cyclins are rate limiting for progression into 
synthesiS (S) phase, the level at which they accumulate must be carefully 
regulated. Several mechanisms leading to over-expression of cyclin D1 have 
been reported including amplification, translocation and stabilisation of the 
TECHNIKON 
IIItrfTMTIfIIU STAT! 
18 
messenger ribonucleic acid (mRNA) (Russel et a/., 1999). Furthermore, over-
expression of cyclin D1, similar to mutation of p53, appears to lead to genome 
instability (Zhou et aI., 1996). 
The use of fluorescence in situ hybridisation (FISH) allows the detection of 
chromosomal amplifications, deletions or trans locations at a single-cell level in 
dividing and resting cells (Panayiotidis and Kotsi, 1999). 
The aim of this study was to detect the presence of p53 and cyclin D1 by means 
of FISH in patients with CML and to correlate the expression status of the genes 
with the clinical status of the patients. 
CHAPTER 2 
CHRONIC MYELOGENOUS LEUKAEMIA 
LITERATURE REVIEW 
2.1. INTRODUCTION 
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CML is a myeloproliferative disorder that results from the neoplastic 
transformation of haematopoietic progenitor cells and affects myeloid, monocytic, 
megakaryocytic, lymphoid and erythroid lineages. CML accounts for 15-20% of 
leukaemias in adults and occurs with an incidence of 1-2 cases per 100 000 
population. CML occurs more frequently in males than in females (ratio of 1.3 to 
1). Incidence increases with age, and the median age at presentation is between 
45 and 55 years (Kantarjian et aI., 1993). However, the disease can occur in all 
age groups and there is an increasing proportion of younger patients (Faderl et 
aI., 1999a). 
CML usually refers to a disease characterized by insidious onset with gradually 
increasing neutrophil leukocytosis, a gradual increase in spleen size and the 
eventual development of anaemia severe enough to demand specific treatment 
(Moossa et a/., 1991). 
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In most cases, cytotoxic drugs can suppress the proliferation of the 
haematopoietic cells for 1 to 4 years, but eventually disease progression or 
transition to acute leukaemia develops in most of the patients. During the 
terminal months of the disease, therapeutic agents are ineffective. Death results 
from inanition, organ infiltration by leukaemic cells, infection or haemorrhage 
(Williams et aI., 1986). 
2.2 CLINICAL COURSE, PROGNOSIS AND CAUSATIVE FACTORS 
2.2.1 CLINICAL COURSE 
CML typically follows a biphasic or triphasic course. A chronic phase (CP), of 
variable length, precedes an accelerated phase (AP) , which is often followed by a 
blastic phase (BP) (Kantarjian et aI., 1993). In most patients (85%), the disease 
is diagnosed in the chronic phase. Accelerated and blastic phase presentations 
occur in only 5-10% of patients (Savage et al., 1997). The clinical course of CML 
varies from patient to patient and the median survival period of 3-4 years from 
diagnosis, is a near universal finding (Knowles, 1992). 
2.2.1.1 Chronic phase 
The signs and symptoms of CML develop insidiously at first, but tend to become 
continuously worse if treatment is not given to the patient (Williams et aI. , 1986). 
CP is indolent and as much as 50% of patients in this stage have no symptoms 
and are only diagnosed by routine blood testing (Kantarjian et al., 1993). A great 
majority of patients are diagnosed when the disease is still in uncomplicated CP 
(Moossa et al., 1991). Marked leukocytosis, thrombocytosis and anaemia are 
21 
common laboratory features at presentation (Savage et al., 1997). Granulocytes 
are present in all stages of maturation. The bone marrow of CML patients is 
usually hypercellular and may reveal reticulin fibrosis, especially with disease 
progression (Cortes et aI., 1996). 
Among those patients who have symptoms, anorexia, fatigue, weight loss, early 
satiety, abdominal fullness, left upper quadrant discomfort, bleeding and sweats 
are encountered most frequently (Cortes et aI., 1996). Because the granulocytes 
have only mild functional abnormalities, infections are uncommon during CPo 
The duration of the CP is about 3 years and the survival for patients with CML is 
about 3,5 - 4 years (Knowles, 1992). 
In the rare patient who presents with a very high white blood cell count, 
symptoms of hyperviscosity may occur; these include visual disturbances due to 
retinal hemorrhage, headaches, tinnitus, stupor and priapism. Splenomegaly is 
revealed in 50% of patients with CML and hepatomegaly in a lesser percentage 
(Cortes et aI., 1996). 
2.2.1.2 Accelerated phase 
CML invariably transforms and becomes refractory to therapy with agents such 
as hydroxyurea and busulfan. It then enters the accelerated phase that is 
characterized by basophilia and increases in peripheral blood blast and 
promyelocyte counts. The definition of the accelerated phase is vague and relies 
on several generally accepted clinical and laboratory criteria (Kantarjian et aI., 
1988). Some of these criteria are: peripheral blood blasts of 15% or more, 
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peripheral blood blasts and promyelocytes of 30% or more, peripheral blood 
basophils of 20% or more, platelet count of 100 x 109 per liter (/L) or less 
(unrelated to therapy) and clonal evolution (Kantarjian et aI., 1993). A finding of 
15-29% marrow blasts or of 30% promyelocytes and blasts in the bone marrow, 
is sufficient evidence for a diagnosis of the accelerated phase (Knowles, 1992). 
2.2.1.3 Blastic phase 
In about 75% of CML patients, the accelerated phase is followed (after 3 to 18 
months) by the blastic phase. This phase resembles acute leukaemia and 
causes the death of the patients within 3 to 6 months. One-fourth of patients 
develop the blastic phase without an intervening accelerated phase (Kantarjian et 
aI., 1988). 
In most patients, the disease will enter a phase in which blast cells or blast cells 
plus promyelocytes constitute 30% or more of the cells in the blood and/or bone 
marrow (Moossa et aI., 1991). In one-third of cases, blasts are characterized by 
lymphoid morphology and expression of lymphoid markers, such as terminal 
deoxynucleotidase. The remaining two-thirds of the patients have either the 
acute myeloblastic leukaemia or the acute undifferentiated leukaemia phenotype 
and form a heterogeneous group (Griffin et aI., 1983). 
Some patients are still entirely free of symptoms; more often they feel non-
specifically unwell. The duration of survival of patients in the BP is extremely 
variable: some will die within days of diagnosis despite optimal treatment, while 
in others the disease will respond to treatment and survival may be prolonged for 
some months or even (rarely) for more than a year (Moossa et aI., 1991). 
2.2.2 PROGNOSIS 
The survival pattern of patients with CML has changed over the last decade. The 
median survival time of patients has doubled from 5 to 7 years, with up to 50% of 
patients alive at 5 years. This development is due to refinements in allogeneic 
stem-cell transplantations and growing expertise in the use of interferon-alfa, a 
biological agent that has been shown to suppress the leukaemic clone and to 
prolong survival in patients with CML (Faderl et aI., 1999b). 
2.2.3 CAUSA TlVE FACTORS 
The causative factors of CML are unknown (Knowles, 1992). This disease 
occurs in every country of the world, furthermore, it is not known to be associated 
with any conventionally infectious virus or other agent (Moossa et aI., 1991). A 
higher than expected incidence of CML in patients given radiotherapy for 
ankylosing spondylitis, and atomic bomb survivors in Japan, has implicated 
ioniSing irradiation as a cause in some cases, but in most of the patients, no 
etiologic factors have been identified. A report on a relapse of CML in donor cells 
after an allogenic bone marrow transplantation suggested that some 
transmissible oncogenic agent or inducing factor might be responsible for 
reinducing the disease in the engrafted cells (Knowles, 1992). 
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2.3 CYTOGENETIC ABNORMALITIES 
Assays for studying the growth and development of primitive haematopoietic cells 
in vitro have established the presence of numerous haematopoietic growth 
factors and cytokines; elucidated their cellular sources and their receptors, and 
showed how growth factor stimulated receptors transmit their message to the 
nucleus where the genes controlling differentiation and proliferation reside. The 
knowledge of normal haematopoiesis has increased the understanding of how 
specific perturbations in this process may lead to the development of a 
transformed or malignant phenotype that is now clinically recognized as 
leukaemia (Sawyers et aI. , 1991). 
Initially described by Nowell and Hungerford in 1960, the Ph chromosome in the 
leukaemic leukocytes of patients with CML, became the first chromosomal 
abnormality to be associated with a specific neoplastic disorder. The Ph 
chromosome results from a reciprocal translocation between the long arms of 
chromosome 9 and chromosome 22 (Nowell and Hungerford, 1960). The 
t(9;22)(q34;q11) translocation can be demonstrated in more than 90% of patients 
with CML. It is, however, also seen in up to 5% of children and 15-30% of adults 
with acute lymphocytic leukaemia (ALL), and in 2% of patients with acute 
myelogenous leukaemia (AML) who showed no evidence of a preceding CML 
phase (Kurzrock et aI., 1988). Cytogenetic analysis revealed the Ph chromosome 
in 90% of patients with CML. In the 10% of patients with CML in whom the Ph 
chromosome cannot be demonstrated by cytogenetic studies, molecular analysis 
revealed BCRlABL fusion products in half of them (Guo et al., 1991). 
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Evidence of a direct link between the expression of BCRlABL fusion gene 
products and abnormal proliferation and malignant behaviour of haematopoietic 
progenitor cells came from experiments using in vitro and in vivo models for 
tumour development. In vitro bone marrow culture assays have shown that 
BCRlABL causes factor-independent and leukemogenic cell growth in 
haematopoietic cell lines (Daley and Baltimore, 1988). During the chronic phase, 
myeloid cells containing BCRlABL retain the capacity to differentiate normally. 
There is progressive loss of the capacity for terminal differentiation resulting in 
terminal blast crisis. An increase of the BCRlABL mRNA expression in the 
leukaemic cell, in part due to duplication of the Ph chromosome, precedes the 
phenotypic transformation of the malignant clone (Gaiger et a/., 1995). 
2.4 TUMOUR SUPPRESSOR GENES AND p53 
The discovery of oncogenes initiated an intense laboratory effort where the focus 
was to elucidate as yet undescribed oncogenes and to understand how single 
allele mutations could act dominantly in the "gain of function" ability to transform 
cells and cause tumours in animal experiments. These investigations obscured 
the existence of another set of genes which, when perturbed, also appeared to be 
permissive of tumour formation. In contrast to the oncogenes, these genes 
behaved in a recessive manner so that "loss of function" as opposed to "gain of 
function", resulted in the tumour formation. These genes therefore appeared to 
behave as tumour suppressor genes. The verification of their existence included 
somatic cell hybridisation experiments in which tumour cells and normal cells 
were fused (Weinberg, 1991). 
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2.4.1 FUNCTION OF TUMOUR SUPPRESSOR GENES 
The role of a tumour suppressor gene is to prevent tissue overgrowth, nullify cells 
with damaged genomes, and metastasis. These controlling functions, even in the 
presence of already severely damaged cells that are being driven by oncogenes, 
may be thwarted by a fully functional p53 protein (Hussain and Harris, 1998). 
The p53 gene that was cloned from colon cancer cells is a well-known example of 
a suppressor gene whose loss of function has been associated with tumour 
function (Baker et aI., 1989). It appears that suppressor genes, like p53, regulate 
a cell's ability to progress through the cell cycle (Levine et aI., 1991). Mutations 
of p53 might be considered as relatively "late" leukemogenic events in 
comparison to germline mutations like loss of neurofibromin-1 (NF-1). NF-1 
encodes a protein called neurofibromin, which acts as a guanosine triphosphate 
(GTPase) activating protein. Its loss in patients with neurofibromatosis type 1 
leads to activation of renin-angiotensin system (RAS) and is strongly associated 
with the development of leukaemia or myeloproliferative syndromes (Shannon et 
al.,1994). 
2.4.2 p53 
In a complex organism, somatic cells are under intermittent selection pressure for 
the emergence of mutants that can grow autonomously despite adverse 
conditions, and can survive environmental insults. Repeated rounds of mutation, 
selection and proliferation can lead to cancer, but no one change is common to 
all cancers, or is sufficient to cause autonomous proliferation and metastasis 
(Carson and Lois, 1995). 
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In addition to pertinent clinical data, new risk factors at the molecular and cellular 
level are the subjects of many ongoing studies. Prognostic and predictive factors 
in cancer can serve many purposes. They can be used to understand the natural 
history of cancer. To identify homogeneous patient populations, to characterize 
subsets of patients with a potentially favourable or unfavourable outcome, and to 
predict the success of therapy or to generate follow-up strategies (Volm et a/. , 
1998). The p53 tumour suppressor gene is considered to be one of the most 
important tumour suppressor genes (Porter et a/., 1992). The p53 gene has been 
studied in a large number of cancers and about 900 mutations have been found 
in more than 50 tumour types (Harris, 1993; Caron de Fromentel and Soussi, 
1992). 
2.4.2.1 Prevalence 
Analysis of p53 mRNA levels suggests that the gene is expressed in all tissues of 
the body throughout development. High levels are seen in early embryonic 
development and In the testes of adults (Almon et a/., 1993). 
Immunohistochemical methods for detection of p53 have proved negative except 
in cases of testicular tissue where low levels of p53 specific staining have been 
seen. The explanation for this discrepancy lies in the very short half-life of p53 in 
normal tissues. The protein is constantly being produced but then very rapidly 
broken down so that its steady state level remains very low (Hall et a/., 1993). 
Wild-type p53 has a half-life of 6-20 minutes in normal cells, but the mutant form 
is more resistant to proteolysis, and therefore the half-life is longer, about 2-12 
hours (Hinds et a/., 1990). 
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Mutant p53 protein is metabolically stable and exists longer in the nuclei of 
cancer cells than in wild-type, and various human malignancies such as breast, 
lung and colorectal cancers are frequently positive for the expression of p53 
protein, whereas normal tissue is negative (Porter et aI., 1992; Bennett et aI., 
1992). 
2.4.2.2 Structure of the p53 protein 
The nuclear phosphoprotein p53 was originally discovered in an extract of 
transformed cells that reacted with antiserum from animals with tumours that 
were induced by the simian vacualating virus (SV40) (Lane and Crawford, 1979). 
Little attention was paid to it until 1989 when point mutations in the p53 gene 
were detected in colorectal cancers (Culotta and Koshland, 1993). 
The p53 tumour suppressor is a 393 amino acid nuclear phosphoprotein encoded 
by an 11 exon gene which is located on chromosome 17p13.1, Figure 2.1 (Lane, 
1994; Benchimol et aI., 1985). p53 has a hydrophobic core flanked at the amino 
terminus and carboxy terminus by more highly charged head and tail domains. 
The amino terminal head region is acidic and it has the activity of a transcriptional 
transactivation domain when fused to other deoxyrinonucleic acid (DNA) binding 
domains, while the carboxy terminus is more basic and contains motifs involved 
in regulation of DNA binding activity and oligomerisation. The p53 protein 
contains multiple phosphorylation sites located at both the amino and carboxy 
termini of the molecule. The central region of the molecule is conformationally 
flexible and contains the binding site for SV40 large T antigen and the sequence-
specific double stranded DNA (dsDNA) binding site (Lane, 1994). 
~~~----P53 locus 
~----centromere 
Figure 2.1 Chromosome 17 and p53 locus, p13.1 
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2.4.2.3 Control and pathway of p53 
To be able to understand the role of p53 in normal cells, it is necessary to 
understand the basic concepts of the following: the cell cycle, oncogenes, 
tumour suppressor genes and transcription factors. Cell division consists of four 
phases called M, G1, Sand G2. After mitosis (M phase) the cell enters the first 
gap phase (G1) . The next phase is that of DNA synthesis (S phase) and finally 
there is the second gap (G2) phase before mitosis. During the cell cycle there are 
checkpoints that are able to regulate cell division (Hartwell and Kastan, 1994). 
The cell cycle will stop if certain criteria are not met (Tjian, 1995). It was shown 
that the G1 growth arrest response to ionizing radiation of cells in culture was 
dependent on the presence of a wild-type p53 gene and was accompanied by an 
increase in the p53 protein level (Kuerbitz et aI., 1992). Therefore, because it 
regulates multiple components of the DNA damage control response and 
promotes cellular senescence, it has been called the "guardian of the genome" 
(Carson and Lois, 1995). 
It was proposed that p53 act as a nodal point between stressful stimuli and the 
final fate of the cell , and that multiple events occur both upstream and 
downstream of p53 induction. Under normal circumstances, cells contain very 
low levels of p53 protein, but stressful stimuli trigger upstream events that lead to 
the activation or accumulation of p53, which in turn triggers the downstream 
pathway (Levine, 1997). Various forms of stress (e.g. heat shock, hypoxia, 
cytokines) can initiate the upstream pathway and it is likely that protein kinases 
which are activated by DNA damage and subsequently phosphorylate p53, may 
be responsible (Siliciano et a/., 1997). p53 is not required for normal 
development but lack of p53 function confers an elevated risk of developing 
cancer. It thus seems to act as a tumour suppressor gene (Lane, 1994). 
2.4.2.4 p53 mutations in human cancer 
Malignant transformation is prevented by assuring that the DNA is accurately 
repaired before cell division by forcing the death of cells with excessive DNA 
damage and by placing limits on the replicative lifespan of most somatic cells 
(Carson and Lois, 1995). In most of the tumours that were examined, expression 
of wild-type p53 is lost because of a combination of genetic events that affect the 
maternal and the paternal alleles of the gene. The most common combination 
found in solid tumours is the complete loss of one allele of the p53 gene, which is 
usually the result of a large chromosomal deletion, combined with a point 
missense mutation in the other allele. The mutant protein is typically produced in 
large amounts by the tumour cell (Scheffner et a/., 1990, 1991). 
It is widely accepted that p53 expression, which was detected by 
immunohistochemistry, is probably used as a surrogate for p53 mutation. 
Conversely, a stabilized p53 protein might not be mutant in vitro. The study of a 
possible correlation between chromosome 17, the p53 gene and p53 protein 
might be helpful for evaluating the significance of p53 expression in tumours (Li et 
a/., 1997). 
2.4.2.5 Mutation by cancer type 
The location and type of mutations in a specific sequence define a mutational 
spectrum. When the p53 mutations are grouped together, they identify several 
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codons at which exceptionally high numbers of tumour mutations are clustered 
(hot spots). When mutations are examined separately by cancer type, clear 
differences in spectra emerge, both with respect to the position of the hot spots, 
and with respect to the frequency of transitions (purine substituted for a purine or 
a pyrimidine for a pyrimidine) and transversions (purine is substituted for a 
pyrimidine or vice versa) (Hollstein et aI. , 1991). The patterns of mutations in 
leukaemias and lymphomas are remarkably similar to that of colorectal tumours. 
Guanine to Thiamine transversions are uncommon, and Adenine:Thiamine to 
Guanine:Cytocine transitions predominate among substitutions at 
Adenine:Thiamine pairs (Gaidano et al., 1991). 
2.4.2.6 p53, DNA damage and apoptosis 
The p53 gene is not necessary for cell growth and differentiation. Mice with 
disruptions of both copies of the p53 gene are usually normal at birth but they 
develop tumours at an early age because of an inadequate DNA damage-control 
response (Carson and Lois, 1995). In cells that contain a wild-type p53 gene, the 
accumulation of wild-type p53 results in a profound growth arrest and frequently 
to the rapid elimination of the cell by apoptosis. The signal is incompatible with 
continued survival and prol iferation, but in a cell in which the p53 protein is 
inactivated, no such apoptotic signal is delivered. These cells continue to 
proliferate without resolving the defect that first led them to generate the Signal for 
p53 stability; they are genetically unstable and send a continuous but futile signal 
to the p53 system (Lane, 1994; Carson and Ribeiro, 1993). 
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The contribution of p53 to apoptosis is not restricted to cells exposed to acute 
DNA damage or bearing certain activated oncogenes. Studies showed a role for 
p53 in mediating apoptosis in response to withdrawal of haematopoietic survival 
factors. A reduction in apoptotic death following factor deprivation was observed 
in haematopoietic progenitors from p53-null mice (Lotem and Sachs, 1993). This 
was also observed in leukaemic cells in which p53 was inactivated by either 
dominant-negative mutations or anti-sense oligonucleotides (Gottlieb et a/., 
1994). 
Chromosomal length is shortened by 50-60 nucleotide residues with each cell 
division, and when this shortening reaches a critical threshold value, apoptosis 
will ensue, even in cells without p53. Some cells will unfortunately withstand the 
crisis, and the survivors re-express the telomerase enzyme that prevents 
chromosome shortening and can thus grow continuously (Counter et a/. , 1992). 
The ability of the cell to survive after DNA damage depends on the p53 gene 
dosage. Epidermal cells with mutations in one copy of the p53 gene are slightly 
resistant to death by apoptosis (Ziegler and Jonason, 1994). Cells devoid of p53 
do not properly recognize altered DNA and may begin mitosis before completion 
of chromosomal segregation and spindle formation (Cross and Sanchez, 1995). 
Replication of damaged DNA results in a high error frequency, giving rise to the 
gene amplifications or chromosomal translocations observed in many cancers. A 
normal p53 protein will monitor the fidelity of the cell cycle by preventing the 
replication errors that occur when damaged DNA is duplicated (Livingstone et a/., 
1992). 
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2.4.2.7 p53 in haemat%gica/ malignancies 
Based on epidemiological and experimental evidence, leukaemia is mainly the 
result of an accumulation of mutations in critical target genes of haematopoietic 
cells. These mutations range from simple sequence substitutions to complex 
genomic rearrangements. In human leukaemia, point mutations are reported to 
affect proto-oncogenes like c-fms, c-RAS, and p53 (Bos, 1989; Ridge et aI., 
1990; Slingerland et a/., 1991). Some of the most notable features of p53 
alterations in haematopoietic malignancies are: 
(a) Development of p53 mutations is often correlated with worsening or 
relapsing haematopoietic malignancy. 
(b) Loss of the short arm of chromosome 17 is associated with a p53 mutation 
on the remaining allele in several haematopoietic malignancies. 
(c) Hodgkin's disease (HD) has p53 positive Reed-Sternberg (RS) cells but 
accompanying lymphocytes, eosinophils and macrophages do not over-
express p53, consistent with these cells being a reaction to the malignant 
process. Lymphocyte-predominant HD does not have p53-positive RS 
cells. 
(d) B-cell lymphomas with p53 mutations often have avian myeloblastosis 
virus oncogene (c-myb) activation, but Epstein-Barr virus (EBV) infection 
does not appear to correlate with the presence of a p53 mutation. 
Individuals with Li-Fraumeni syndrome (LFS) have a p53 mutation in their 
germline and have an increase incidence of leukaemias and lymphomas 
(Imamura et aI., 1994). 
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CML mostly evolves from a chronic, relatively indolent disease to a more 
aggressive leukaemia whose progressive stages are accelerated phase and blast 
crisis (Muehleck et aI., 1984). The blast cells of the aggressive phases may be of 
several types, most commonly myeloid, less commonly lymphoid, and rarely 
other phenotypes, suggesting that different molecular events induce different 
forms of disease (Liu et aI. , 1988). The structure and expression of the p53 gene 
is altered in about 25% of myeloid BC of CML, whereas CP CML cells rarely have 
detectable p53 alterations, suggesting that the p53 gene might be involved in the 
evolution of some cases of BC (Ahuja et aI., 1989 a,b). 
Several features of CML and p53 are the following: 
(a) The p53 alterations almost always occur in myeloid and not lymphoid blast 
crisis (Nakai et a/., 1992). 
(b) The p53 mutations are associated most frequently with samples in which 
one of the short arms of chromosome 17 (17p) has been lost, usually 
through the formation of either an isochromosome 17q (i(17q)) or 
unbalanced translocation. The i(17q) chromosome occurs in about 30% of 
cases of myeloid blast crisis of CML and about 40% of these have p53 
mutations on the remaining p53 allele. Loss of 17p (containing p53) may 
precede the p53 mutation of the remaining allele in CML patients, whereas 
the p53 mutations in colorectal and breast tumours occur on one p53 allele 
and the remaining normal p53 allele is lost. These observations 
emphasize the strong selection for complete loss of p53 function in the 
process of carcinogenesis (Nakai et aI., 1992). 
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(c) CMl is analogous to osteosarcoma as far as the p53 gene can be altered 
by either point mutations or major DNA rearrangements (Nakai et aI., 
1992). 
(d) Evidence suggests that a p53 mutation in the CMl clone can result in 
disease transformation to myeloid blast crisis (Foti et aI., 1991). When 
wild-type p53 is transfected and stably expressed in the p53 null CMl 
erythroblastic cell line K562 , growth of the cells slows and they undergo 
partial differentiation suggesting an involvement of wild-type p53 in the 
differentiation processes (Feinstein et al., 1992). 
Some of the haematopoietic malignancies in which p53 mutations are associated 
with the progression of disease are: evolution from a follicular to high-grade 
lymphoma; evolution from chronic lymphocytic leukaemia (Cll) to high-grade 
Richter's-type lymphoma; progression to a refractory phase of multiple myeloma 
(MM); development of relapsed B- or T-All; evolution from myelodysplastic 
syndrome (MDS) to acute myelogenous leukaemia, and evolution from chronic 
phase to myeloid blast crisis of CMl (Imamura et aI., 1994). Evolution of CMl 
and MDS to myeloid blast crisis and AMl respectively, have been associated with 
loss of the short arm of chromosome 17 and the mutation of the remaining p53 
allele. Several of the other Iymphoproliferative disorders such as Cll and 
follicular lymphoma can acquire a p53 alteration as they progress to a more 
malignant phenotype. p53 mutations have also been associated with progression 
of solid malignancies such as the transition from benign adenoma to malignant 
colon carcinoma (Baker et aI., 1989). 
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2.5 ONCOGENES AND CYCLIN 01 
Activation of proto-oncogenes and loss of tumour suppressor genes are genetic 
changes associated with carcinogenesis. Proto-oncogenes are normal cellular 
genes that control cell proliferation, differentiation and apoptosis. Almost all 
proto-oncogenes encode a protein component of the signal transduction cascade. 
This integrated, multi-process system is responsible for the specific transmission 
of extracellular signals to the nucleus, and this process regulates gene 
transcription with respect to replication (Cobb, 1999). When proto-oncogenes are 
activated, they are called oncogenes. Oncogenes exert a positive driving force 
for cell growth by their failure to desist in response to the absence of stimulation 
(Krontiris, 1995). 
2.5.1 The role of oncogenes in regulating cell growth and malignant 
transformation 
Orderly cell growth requires the careful orchestration of events that occur first at 
the cell membrane and then progress through the cytoplasm and into the 
nucleus. There the genes that are required to carry out the command of the 
stimulus, initiated at the membrane, must be activated. This chain of command 
requires many interacting elements, including the signal initiator, which is often a 
growth factor; the growth factor's receptor; a signal transducing apparatus, often 
consisting of membrane tyrosine kinases; GTP binding (RAS family) nuclear 
transcription factors, and other yet undefined elements (Dang, 1991). 
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Given that oncogenes encode products that are highly homologous to growth 
factors, growth factor receptors or elements of the signal transduction apparatus, 
it seems reasonable that altered expression or activation of these genes or their 
products could play a role in carcinogenesis. Examples of this include 
chromosomal trans locations leading to structural alterations of the gene; the 
acquisition of point mutations in coding sequence; retroviral insertion disrupting 
promoter element or coding function; deletions and amplifications, and/or over-
expression (Bishop, 1987, 1991). Any of these mechanisms could induce a 
critical change in the gene leading to its activation. This activation in turn will 
result in production of a protein with aberrant function as in the case of RAS-type 
mutations, which leave a critical signal transducing protein in a permanently "on" 
position (Bos, 1989). Amplification of an affected gene, resulting in inappropriate 
expression or over-expression, may also be capable of transforming and may 
contribute directly to the expression of the malignant phenotype (Henderson et 
a/. , 1991). Currently over fifty oncogenes have been identified in human cancers 
(Haber and Fearon, 1998). 
2.5.2 Clinical relevance of oncogenes 
The ability to detect and understand the function of oncogenes also has clinical 
implications. These become obvious when the following is considered: 
diagnostic tools, monitoring of cancer therapy, prediction of prognosis and 
therapy (Bishop, 1991; Gullick and Sikora, 1990). Consistently recurring 
karyotypic abnormalities are found in many haematologic and solid tumours. 
These abnormalities include chromosomal re-arrangements as well as the gain or 
loss of whole chromosomes or chromosome segments (Nowell and Hungerford, 
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1960). A good example is found in CML where the reciprocal translocation 
between chromosomes 9 and 22 in which ABL (9q34) joins to the breakpoint 
cluster region (BCR) on 22q11 to form a new fusion gene and an 8.5-kb chimeric 
mRNA is transcribed (Kantarjian et al., 1994). 
Another example is the RAS mutations commonly seen in cases of AML and 
MOS. This aberration might be useful to detect the early stage of leukaemia and 
to monitor the effect of chemotherapy. Oue to the fact that patients with MOS 
with RAS mutations have a higher possibility of progressing to AML and have 
poorer prognosis, this oncogene aberration might be useful to predict the 
prognosis (Bos, 1989). 
2.5.3 Cyclins and cell cycle control 
The GofS phase transition in higher eukariotic cells is controlled by the assembly 
of G, cyclins, cyclins C, 01-3 and E, with their cyclin dependent kinase (COK) 
partners, COK2 and COK4 (Oraetta, 1994; Sherr, 1994 and 1995). The cyclins 
are divided into three groups based on the phases of the cell cycle in which they 
act: G, cyclins (C, 01 , 02, 03 and E cyclins), an S phase cyclin (A) and G2/M 
cyclins (B1 , B2 and A cyclins) (Oraetta, 1994; Hunter and Pines, 1994; Sherr, 
1994) 
The G, cyclins were independently isolated by their ability to complement 
conditionally defective G, cyclins in yeast (C, 01 and E cyclins) and as early 
growth factor-induced genes (01 , 02 and 03 cyclins) (Lew et al., 1991 ; 
Matsushime et aJ. , 1991). Cyclin B participates in the regulation of the G2/M 
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transition by its association with p34cdC2, whereas cyclin A appears to be essential 
for the completion of S phase entry into G2 phase in complexes with both p34CdC2 
and CDK2 (Rosenblatt et aI. , 1992; Walker and Maller, 1991 ; Roy et a/., 1991 ; 
Solomon et aI., 1990). In contrast, the complexes formed between D-type cyclins 
and CDK4 and CDK6 integrate growth factor signals and the cell cycle, allowing 
cells to progress normally through G1 phase (Kato et aI. , 1993; Meyerson and 
Harlow, 1994). With the genetic alterations that occur in their pathway during 
oncogenesis, it appears to involve many of its components, including the D-type 
cyclins, cyclin-dependent protein kinases and cyclin-dependent kinase inhibitors 
(Lathi et a/., 1997). 
2.5.4 D-type cyclins 
Unlike other G1 cyclins (e.g. cyclin C and cyclin E), the D-type cyclins are highly 
homologous to one another and their expression overlaps during G1 phase, thus 
suggesting that this group of cyclins may be somewhat redundant in their function 
(Khatib et aI. , 1993). It must, however, be noted that not all D-type cyclins are 
expressed in each tissue, suggesting that their function may be linked to the 
specific tissues in which they are expressed. This particular cell cycle pathway is 
subject to a number of alterations during tumourigenesis, presumably due to its 
importance in response to mitogenic stimulation (Parry et aI., 1995; Koh et a/., 
1995; Medema et a/., 1995). 
It was established that each of the D-type cyclins contain a functional 
retinoblastoma (RB)-binding motif and that these cyclins are induced in response 
to mitogens in a cell lineage-specific manner (Sherr, 1994). Cyclins 02 and 03 
preferentially bind to RB, whereas cyclin 01-RB complexes are less stable (Ewen 
et aI. , 1993; Dowdy et aI., 1993). Microinjection of cyclin 01 antibodies and/or 
antisense oligonucleotides into normal human diploid fibroblasts, NIH3T3 and 
Rat-2 cells, revealed that a sub-group of these cells could not enter the S-phase 
(Baldin et aI. , 1993; Quelle et a/., 1993). The ability of the microinjected cells to 
pass the restriction point and begin DNA replication was directly related to the 
time that elapsed between the re-addition of serum and microinjection of cyclin 
01 antibodies or antisense oligonucleotides. By decreasing the level of functional 
cyclin 01 proteins prior to the restriction point in late G1 phase, the ability of these 
cells to progress through the cell cycle was impaired. These agents seem to 
have no effect on the cell cycle once cells have passed the restriction point late in 
the G1 phase of the cell cycle. It was also shown that ectopic expression of cyclin 
01 inhibits myogenic determination factor (MyoO) and myogenin-mediated 
skeletal muscle differentiation indirectly. Experiments to determine the role of 
cyclin 01 in muscle differentiation were designed to determine whether 
MyoO/myogenin and/or RB were targets of cyclin 01 COK phosphorylation. 
Mutation of COK phosphorylation sites in myogenin had no effect on the ability of 
cyclin 01 to inhibit differentiation. Ectopic MyoO expression in fibroblasts can 
induce muscle-specific gene expression, as long as wild-type RB is expressed 
(Skapek et aI. , 1996). In RB -/- fibroblasts expressing MyoO and a mutated RB 
(which cannot be hyperphosphorylated), ectopic cyclin 01 expression continues 
to inhibit muscle-specific gene expression, whereas ectopically expressed cyclins 
A and E have no effect. This suggests that the initiation of muscle-specific gene 
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expression, can be blocked by two distinct pathways, one of which is dependent 
on RB hyperphosphorylation and the other not (Lahti et aI. , 1997). 
2.5.5 Cyclin D1 in tumourigenesis 
The D-type cyclins playa major role in tumour development and progression. 
Their over-expression due to chromosomal translocation, DNA amplification, 
retroviral integration or gene mutation contributes to the development of many 
tumour types (Musgrove et aI., 1994; Bartkova et aI., 1995; Lukas et aI. , 1996). 
Regulation of the vertebrate cell cycle requires the periodic formation, activation 
and inactivation of unique protein kinase complexes that consist of cyclin 
subunits, and cell cycle-dependent fluctuations in the levels of many of the cyclin 
proteins are thought to contribute, at least in part, to the activation of these 
enzymes (Maller, 1991 ; Nurse, 1990; Sherr, 1994). The cyclins are required to 
regulate many of the p34cdc2-related cyclin-dependent protein kinases which have 
diverse functions prominently linked to the control of cell division (Devoto et aI. , 
1992; Gabriellieta/., 1992; Meyersonetal., 1992). 
Cyclin D1 was implicated in tumourigenesis as it was found amplified or over-
expressed in parathyroid, stomach, breast, head and neck tumours (Motokura 
and Arnold, 1993a). Among the G1 cyclins, cyclin D1 appears to be most strongly 
implicated in human tumourigenesis (Motokura and Arnold, 1993b). This protein 
is encoded by the CCND1 gene (also known as bcl-1 or PRAD1) on chromosome 
11 q13 Figure 2.2 (Baldin et al., 1993). The 11 q13 region harbours several genes 
that could playa role in tumourigenesis, including the proto-oncogenes INT2, 
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Figure 2.2 Chromosome 11 and cyclin 01 locus, 11q13 
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HST1 and EMS1, which encodes a putative steroid receptor co-activator (src) 
kinase substrate (Lammie and Peters, 1991; Schuuring, et aI. , 1993). It was 
shown that a moderate increase in the level of cyclin 01 can promote cellular 
proliferation by accelerating the G1 transition, while micro-injection of 01 
antisense ribonucleic acid (RNA) or antibodies can prevent S phase entry (Quelle 
et aI., 1993; Reznitsky et aI., 1994; Baldin et aI. , 1993). However, the induction 
of high levels of cyclin 01 at the G1/S border can functionally antagonize cellular 
proliferation by preventing S phase entry and this suggested that the 
physiological effect of cyclin 01 may depend on the timing and the levels to which 
it is induced (Quelle et aI., 1993; Baldin et a/., 1993). Evidence pointed to a 
direct role for O-type cyclins in transcriptional activation and repression. For 
example, it was shown that cyclin 01 inhibits transcriptional activation by the 
dentin matrix protein 1 (OMP) transcription factor (Inoue and Sherr, 1998). 
Conversely, a multitude of evidence showed that cyclin 01 binds the estrogen 
receptor and activates its transactivation potential in a ligand-independent 
manner (Neuman et aI., 1997; Zwijsen et aI. , 1997). In both of these cases, the 
influence of cyclin 01 on transcription have been shown to occur independently of 
its role in cell cycle progression, thus defining a novel function for the O-type 
cyclins as transcriptional regulators (Knudsen et aI., 1999). 
Another regulatory mechanism involves the binding of specific inhibitory proteins 
(p21 WAF1 , p27K1P1 , p57K1P2) to COK complexes or the binding of specific inhibitory 
proteins directly to COK4 (p15, p161NK1 , p18 and p19) (Gu et a/., 1993; Serrano 
et a/., 1993; Hannon and Beach, 1994). There is now enough evidence to 
indicate that disturbances in specific cyclins, COKs, or the above mentioned 
inhibitory proteins do play an important role in several types of human cancer 
(Weinstein and Zhou, 1996). The most frequent abnormalities relate to cyclin 01 . 
It is rearranged and over-expressed in parathyroid tumours and centrocytic 
lymphomas and is amplified and/or over-expressed in a major fraction of human 
tumours of the breast and esophagus, squamous carcinomas of the neck and 
head as well as various other types of cancer (Oraetta, 1994; Hunter and Pines, 
1994; Motokura et aI. , 1991 ; Jiang et aI. , 1993b). It was observed that ectopic 
over-expressiorrof cyclin 01 in fibroblast cultures not only shortens the G1 phase 
of the cell cycle, but also enhances cell growth, cell transformation and 
tumourigenicity (Jiang et aI. , 1993a). 
Over-expression of cyclin 01 in rat fibroblasts enhanced their growth and 
tumourigenicity (Jiang et al., 1993a). Cyclin 01 collaborated with an activated 
RAS oncogene or a defective adenovirus E1A oncogene to increase the 
transformation of the primary rodent fibroblast (Lovec, 1994; Hinds et al., 1994). 
It was demonstrated that the introduction of an antisense cyclin 01 ONA 
sequence into a human esophageal carcinoma cell line, in which the cyclin 01 
gene is amplified and over-expressed, reduced the level of expression of this 
protein and caused reversion of the malignant phenotype (Zhou et aI. , 1996). 
These results suggest that increased expression of cyclin 01 can playa critical 
role in tumour development and in maintenance of the malignant phenotype, 
thus, over-expression of cyclin 01 can produce complex effects on various 
cellular functions involved in growth control and cell cycle progression (Imoto et 
aI. , 1997). Transgenic mice carrying a Maloney Mammary Tumour Virus-cyclin 
01 , displayed mammary epithelial hyperplasia and developed mammary 
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carcinomas (Wang et aI., 1994). Immunohistochemical detection of cyclin 01 in a 
series of human breast cancers has led to the identification of a subset of 
carcinomas in which there is increased expression of cyclin 01 gene in the 
absence of gene amplification (Gillet et aI., 1994). The increased expression of 
cyclin 01 mRNA and protein in the absence of cyclin 01 gene amplification, has 
also been seen in human colon carcinomas (Arber et aI., 1996.) Thus, 
mechanisms other than gene amplification and chromosomal rearrangement can 
lead to increased levels of the cyclin 01 protein in certain human cancers (Arber 
et aI., 1996). 
2.6 FLUORESCENCE IN SITU HYBRIDISATION 
Chromosomal abnormalities are the hallmark of cancer cells. Recurring and 
highly consistent structural and numerical alterations have been identified in a 
large number of solid tumours, leukaemias and lymphomas. The identification of 
recurrent genetic alterations and the isolation of molecular markers have clinical 
applications in the diagnosis and the prognosis of neoplasia and in the detection 
of minimal residual disease that are essential for designing the most effective 
therapeutic approach (Popescu and Zimonjic, 1997). 
The polymerase chain reaction (PCR) and fluorescence in situ hybridisation 
(FISH) are powerful techniques for the detection of genomic alterations. Virtually 
any chromosomal alterations, regardless of their complexity, can be resolved by 
the battery of FISH methods and DNA probes that are available. Combined 
chromosome banding, multifluor or spectral karyotyping and comparative 
47 
genomic hybridisation allow for the identification of structural and numerical 
alterations on a global basis; mapping of the DNA copy number of the entire 
tumour genome; complete derivation of complex rearrangements, and the 
localization of the breakpoints of translocations and deletions. Regions of 
recurrent alterations can be micro-dissected, amplified, microline libraries 
constructed and probes localized on extended chromosomes or chromatin fibres 
for construction of high-resolution physical maps that are critical for positional 
cloning and gene identification (Popescu and Zimonjic, 1997). 
FISH enables the detection of structural and numerical chromosome aberrations 
in both metaphase spreads and interphase cell nuclei, and provides a simple, fast 
and reliable means to assess genetic instability in cancer (Gray and Pinkel, 1992; 
Kallioniemi et aI. , 1992). FISH can detect genetic anomalies over a much greater 
dynamic size range than other techniques. The FISH reagents that are available 
can identify either entire chromosomes or regions smaller than a single gene (Fox 
et al., 1995). For the enumeration of chromosome copy numbers in interphase 
nuclei in neoplasms, chromosome specific centromeric DNA probes can be used 
(Gray and Pinkel, 1992). In addition, interphase cells can be utilized, eliminating 
the need to cultivate cells and often permitting simple "touch" preparations to be 
used for biopsy samples (Fox et aI., 1995). This is a commonly used technique 
for the determination of gene and chromosome dosage. In tissue sections it 
allows precise histopathologic correlation of multiple foci of normal epithelium, 
premalignant lesions and carcinoma within a single sample, including a study of 
intratumoural heterogeneity (Qian et aI., 1999). FISH can also be a very effective 
method for the detection of homozygous chromosome deletions in primary 
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tumour tissues and the demonstration of homozygous deletion has been very 
useful in pinpointing tumour suppressor gene locations (Xiao et ai., 1995; 
Schofield and Fletcher, 1992). 
2.6.1 Chromosomal translocations 
Localization of genes in the human genome has been essential for molecular 
analysis of chromosomal alterations in cancer cells. Oncogenes have been 
found to be associated with cancer-specific translocations (Croce and Nowell, 
1985). Lymphomas, leukaemias and an increasing number of sarcomas are 
characterized by specific chromosomal translocations and several general 
principles have emerged from molecular studies of recurrent translocations. 
These re-arrangements, which are frequently part of relatively simple karyotypes, 
particularly in lymphomas and leukaemias, lead to activation of proto-oncogenes 
or to the formation of new oncogenic chimeric genes. Both the gene fusion 
proteins and oncogene products are often transcriptional factors (Rabbits, 1994). 
FISH offers a way to identify chromosomal translocations on the whole karyotype 
by the use of combination multifluor detection or spectral analysis. Hybridisation 
with chromosome and single-copy gene probes and bi- and multicolour detection 
can characterize specific translocations. FISH with two chromosome probes 
permits the identification of complex re-arrangements (Zhang et ai. , 1993). 
2.6.2 Gene mapping 
FISH is the most efficient and reproducible approach for the precise localization 
of single sequences within metaphase chromosomes. Along the chromosome 
length, the relative position of the hybridisation signal can be determined by 
measurements on unbanded preparations or by indirect localization of G-banded 
chromosomes as described for isotopic in situ hybridisation (Popescu et aI., 
1985). The resolution of gene mapping was significantly enhanced by the 
development of methods for direct visualization of the fluorescent signal on 
banded metaphase chromosomes, and procedures for induction of G-, R- or Q-
banding have been successfully used to map single-copy genes. These 
procedures include the use of fluorescent dyes, combinations of heat or alkaline 
pH treatments or cohybridisation with Alu-PCR products (McNeil et a/., 1991; 
Lichter et aI. , 1991). Popescu and Zimonjic (1997) reported on the use of a 
procedure that is based on contrast enhancement of 4'6-diamidino-2-
phenylindole (DAPI)-banded chromosome images that permit the direct 
localization of the fluorescent signal on G-like bands. 
2.6.3 FISH and high-resolution mapping 
FISH is now increasingly used to construct high-density cytogenetic maps. 
Multicolour FISH metaphase chromosomes are feasible if the fluorescent signals 
are separated by at least one mega base (Trask, 1991). Further refinement of the 
interphase resolution of mapping can be achieved by alkaline-borate treatment 
that will increase the nuclear diameter fivefold (Yokota et aI. , 1995) . 
2.6.4 DNA amplification 
As in the case of other structural alterations, DNA amplification is a manifestation 
of genomic instability. The small chromatin structures that are referred to as 
double minutes, and abnormally banded or homogeneously stained regions, are 
cytological manifestations of DNA amplification. DNA amplification is commonly 
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associated with the acquisition of drug resistance and tumour progression, and it 
also occurs in the early stages of cell transformation, conferring a selective 
growth advantage to the cells. DNA amplification should be regarded as a critical 
alteration in cancer development because commonly it involves proto-oncogenes 
and persists over indefinite rounds of replication (Bishop, 1987). Amplification of 
single or multiple genes can be readily visualized and quantified by FISH. The 
level of gene amplification on a cell-by-cell basis may however vary considerably 
(Kallioniemi et aI., 1994). 
2.6.5 RNA localization 
FISH can be successfully applied to detect nuclear RNA. The direct visualization 
of viral and cellular RNA transcripts was demonstrated by an original method 
designed to optimize the preparation of interphase cells and the hybridisation 
conditions (Lawrence et aI. , 1989). The ability to detect RNA transcripts to 
interphase nuclei, confers new potential applications for investigating disorders 
resulting from RNA-processing defects, screening for expressed sequences and 
detection of viral expression (Popescu and Zimonjic, 1997). 
CHAPTER 3 
METHODOLOGY 
3.1 MATERIALS 
Chemicals were bought from Merck and were of AR grade. 
Ultra pure sterile water was used throughout. 
VECTASHIELO Mounting medium with OAPI (4'6-diamidino-2-phenylindole) was 
bought from 80S. 
Probes were bought from Vysis: 
Locus specific identifier (LSI) Cyclin 01 (11q13) Spectrum Orange (SO) 
(300 kb) I Chromosome enumeration probe 11 (CEP 11) Spectrum Green 
(SG). Cyclin 01 probe was used to determine the copy number of the 
Cyclin 01 locus and as an enumerator probe for chromosome 11 in 
interphase nuclei (Part #: 32-191039). 
LSI p53 (17p13.1) Spectrum Orange (130 kb). This probe was used to 
detect deletion or amplification of the p53 locus in interphase nuclei (Part 
#: 32-190008). 
CEP 17 (17p11.1-q11, 1) Spectrum Green was used as intemal control to 
determine the copy number for chromosome 17 in interphase nuclei (Part 
#: 32-132017). 
3.2 POPULATION AND SAMPLE SIZE 
Twenty-one blood samples (heparin blood) and 4 archival bone marrow samples 
were obtained from the Department of Hematology, Universitas Hospital in 
Bloemfontein. No informed consent was obtained from patients as all the 
samples were treated anonymously. Samples were randomly collected from 
January 2001 to November 2001 , at the time the samples were sent to the 
laboratory for FISH analysis for Ph chromosome and PCR analysis for the 
BCRlABL breakpoint lesion. Inclusion criterion was the clinical and 
haematological diagnosis of CML. 
A normal peripheral blood sample was used as an internal control to assess 
hybridisation efficiency. 
3.2.1 Patient characteristics 
Of the 25 CML samples, 11 were of female patients and 14 were of male 
patients. Two of the peripheral blood samples (8 and 10) were of the same 
patient sent in at different times. 
The ages ranged from 8 to 81 years, with a mean age of 41.92 years (age for 
numbers 8 and 10 were calculated once). Nineteen of the patients were in 
chronic phase, 3 in accelerated phase, 1 in blastic phase, 1 transformed to ALL 
(T/ALL) and 1 transformed to myelofibrosis (T/myel) . 
Twenty-two of the samples were positive for Ph chromosome studies by FISH, 1 
was non-conclusive, 1 was not performed and 1 was negative. Eleven of the 
samples were positive for the BCRlABL PCR translocation, 6 were negative and 
8 were not performed. Table 3.1 summarises the patient characteristics. 
3.3 SAMPLE PREPARATION 
The Ficoll paque method was used to isolate leukocytes from the blood. Five 
millilitres (ml) of blood (heparin) was layered onto 5 ml Ficoll paque (Ficoll Paque, 
Pharmacia Biotech) in a 15 ml Falcon tube. It was then centrifuged at 1400 
revolutions per minute (rpm) for 30 minutes in a Heraues bench centrifuge. The 
supernatant (Ficoll and plasma) were removed and the buffy layer was 
transferred to a clean tube. Five ml of phosphate buffered saline was added and 
centrifuged at 2500 rpm for 5 minutes. The supernatant was carefully removed 
without disturbing the pellet. Ten ml of prewarmed (37°C) potassium chloride (75 
millimolar) was added while mixing on a vortex mixer (the first ml was added drop 
by drop to prevent clumping of the cells) and the tube was incubated at 37°C for 
10-20 minutes. After centrifugation at 2500 rpm for 5 minutes the supernatant 
was removed, leaving a small amount for re-suspension. Seven ml of fresh cold 
fixative (3:1 Methanol:Acetic acid, volume per volume (v/v)) was added drop by 
drop (first ml) while mixing on a vortex mixer. After centrifugation at 2500 rpm for 
5 min, the supernatant was removed and fresh fixative was added twice more. 
After the last centrifugation, fixative was added to make a slightly milky 
suspension. The cells were stored at 4°C until use. Before use, the cells were 
centrifuged and re-suspended in fresh cold fixative twice before the slides were 
made. 
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Sample Age 
number 
1 35 
2 49 
3 48 
4 30 
5 38 
6 8 
7 39 
8 81 
9 56 
10 81 
11 16 
12 53 
13 39 
14 48 
15 57 
16 44 
17 25 
18 48 
19 67 
20 14 
21 62 
22 19 
23 44 
24 52 
25 34 
.. 
+: Positive, -: Negative 
F: Female, M: Male 
Sex Clinical 
course 
F CP 
M CP 
F CP 
F CP 
F CP 
F CP 
M CP 
F CP 
M CP 
F CP 
M BP 
M CP 
F CP 
M AP 
M CP 
F CP 
M T/ALL 
M CP 
F CP 
M CP 
M CP 
M AP 
M T/myel 
M AP 
F CP 
BCRIABL: Translocation determined by PCR 
Nrs. 1-21: peripheral blood 
Nrs. 22-25: bone marrow 
Ph BCRlABL 
chromosome (PCR) 
(FISH) 
+ · 
Non-conclusive + 
+ + 
+ Not performed 
+ + 
+ + 
+ Not performed 
+ · 
+ + 
+ -
+ + 
+ Not performed 
+ Not performed 
+ + 
+ + 
+ + 
+ -
+ Not performed 
+ · 
+ Not performed 
+ + 
+ Not performed 
Not performed Not performed 
- · 
+ + 
The bone marrow smears were left to soak for 40 minutes in fresh cold fixative 
(3:1 Methanol:Acetic acid, v/v) after which they were dried at room temperature 
and handled according to the Vysis protocol. 
3.4 SLIDE PREPARATION 
Slides were produced by dropping a single drop of the cell suspension onto a 
precleaned slide. When dry, the slides were observed by phase contrast 
microscopy to ensure that there were enough single cells for hybridisation. The 
number and spread of the cells were adjusted by adding more or less fixative at 
this stage. Two slides from each sample were prepared, one for p53 and one for 
Cyclin 01. Normal peripheral blood control slides were prepared at the same 
time to assess hybridisation efficiency for p53 and cyclin 01 respectively. 
3.5 HYBRIDISATION WITH LSI/CEP PROBES 
The hybridisation areas were marked with a diamond pen and the slides were 
immersed in the denaturation solution (70% formamide/2X saline sodium citrate 
(SSC) at 73° C for 5 minutes. Dehydration was performed in an ethanol series 
with one minute steps of 70%, 80% and 100% at room temperature (slides were 
kept in 100% ethanol until the probe was applied). The hybridisation mixtures for 
p53 (in combination with a probe specific for chromosome 17) and Cyclin 01 (in 
combination with a probe specific for chromosome 11) (fluorophore-Iabeled 
painting probes and blocking DNA in Tris- ethylenediaminetetraacetic acid 
(EDTA) buffer) were prepared according to the Vysis protocol (1998, Vysis, Inc.). 
Seven microlitre (IJI) of hybridisation buffer (dextran sulfate, formamide, SSC, 
pH7.0), 2 IJI purified water and 1 IJI of DNA probe (Cyclin D1/CEP11) was 
dispensed into a microcentrifuge tube at ambient temperature. For the 
preparation of the pS3/CEP 17 only 1 IJI of purified sterile water was used and 1 
IJI each of the probes for pS3 and chromosome 17. The tube was centrifuged for 
3 seconds, vortexed and centrifuged again. The slides were removed from the 
ethanol and dried at SO°C in a temperature controlled chamber. 10 IJI of the 
probe mixture was applied on the nuclei spots, coverslipped and sealed with 
commercial glue. A Hybaid Omnigene with hybridisation block and humidified 
chamber was used to co-denature the sample and the probe. The temperature 
was first set at 8SoC for one minute and then reduced to 37°C, and the slides 
were left to hybridise overnight. After hybridisation, the coverslips were carefully 
removed. Post hybridisation washes consisted of one rinse in OAX SSC/0.3% 
Nonidet P-40 (NP-40) at 73°C for 2 minutes and one rinse in 2X SSC/0.1 % NP-
40 at ambient temperature for 1 minute. The slides were removed and allowed to 
air dry in the dark at ambient temperature. The nuclei were counterstained with 
10 IJI of DAPI with antifade and coverslipped. Slides were stored at minus 20°C 
in the dark until scoring was performed 
(http://www.vysis.com/tech_sup_protoJsi .asp#4). 
3.6 VISUALIZATION AND SCORING OF RESULTS 
Hybridisation sites were analyzed using a Nikon E400 fluorescence microscope 
equipped with appropriate filter sets (DAPI, FITC, Rhodamine) for visualizing 
spectrum green and orange fluorescence signals. The target area was scanned 
tJ( 
using a low power objective to examine cell distribution. Cells were scored using 
a 100X oil objective, counting the number of signals for one probe colour within 
the nuclear boundary. Hybridisation signals were counted in 100 nuclei each for 
p53 and cyclin D1. For p53, cells were simultaneously scored, individually for the 
number of p53 and CEP 17 signals. For cyclin D1, cells were simultaneously 
scored, individually for the number of cyclin D1 and CEP 11 signals (signals 
appeared as either bright and compact oval shapes, split into two smaller but 
connected dots, or a stringy diffuse shape). The signal count for each cell was 
recorded and the scanning process continued until 100 nuclei were enumerated 
and the data collected. 
Photos were taken using 400 ASA colour film . Photos representative of selected 
examples (p53 and cyclin D1) were taken and digitally enhanced. 
The following criteria were applied for in situ hybridisation signals 
according to the manufacturer's protocols 
~ Cells that touched or overlapped were not counted . 
~ Diffuse signals were counted if they were separate from other Signals. 
~ Split signals in very close proximity were counted as one. 
~ Signals connected by a strand of fluorescence were counted as one. 
~ Nuclei that were not intact, were not evaluated. 
~ Nuclei with overlapping signals of different colour were not evaluated. 
~ Non-specific hybridisation signals were not counted. Their lower intensity 
and different shapes recognized these signals. 
~ Nuclei with signals located on the periphery of the nucleus were not 
evaluated. 
3.7 QUALITY CONTROL 
Quality assurance certificates were issued with each Vysis set of probes showing 
that the lot number had been tested and found to comply with all the 
specifications. 
~ Hybridisation procedures were performed as indicated in the package 
insert provided with the probe product. 
~ Only four slides were washed at the same time to maintain accurate 
temperature of the wash buffers. 
~ To limit the degradation of the photo-sensitive fluorophores, all solutions 
containing fluorophores were handled in reduced light. All the steps that 
did not require light for manipulation, were performed in darkness. 
~ A calibrated thermometer was used for measuring the temperature of the 
solutions. 
~ Only slides with a good quality were scored. Factors taken into 
consideration were: even distribution of cells across the slide, 
concentration of the cells per field and clumping, and background or 
nuclear fluorescent "noise". 
~ Since the quality control guidelines were written for the ProbeChek control 
slide product, and none were available for p53 and cyclin D1 , normal 
peripheral blood was used as control in order to monitor hybridisation 
efficiency. No quality parameters for p53 and cyclin D1 for the laboratory 
were available. 
CHAPTER 4 
RESULTS 
p53 signals were counted for 100 interphase nuclei per sample slide. Staining 
quality assurance controls, consisting of a normal peripheral blood sample, were 
included for each probe set. Since there were nuclei that failed to react with the 
probes (caused by inadequate hybridization or chromatin loss), cells were scored 
only when at least one bright orange signal for p53 or one green signal for 
chromosome 17 was present. The total number of cells (per sample) with 
hybridisation signals for p53 was compared to the total number of cells with 
Signals for chromosome 17 in order to determine the presence of amplification or 
deletion. LSI SO p53 DNA probe hybridised to band 17p13.1 of human 
chromosome 17, while the CEP SG 17 DNA probe hybridised to the centromere 
(band region 17p11.1-q11.1, locus D17Z1) of chromosome 17. 
Allelic loss is defined as fewer p53 signals per cell than chromosome 17 
centromere signals in the same cell, with the exact threshold being open to 
debate. A cut-off rate was established as 15% of cells analyzed, and the loss of 
allele (LOA) rate was considered significant when it was higher than 15% (Smith 
et aI., 2000; Stuppia et aI., 1997). However, Lazaridou et al. (2002) arrived at a 
figure of 12 ± 3% and for this study a cut-off rate of 9% was adopted (Lazaridou 
et al., 2000). 
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FISH was carried out on 18 Ph+ samples in chronic phase, 1 non-conclusive Ph 
sample in chronic phase, 1 Ph+ sample in blastic phase, 2 Ph+ samples in 
accelerated phase, 1 Ph- sample in accelerated phase, 1 Ph+ sample which 
transformed to ALL and 1 not-performed Ph sample which transformed to 
myelofibrosis. One of the bone marrow samples, Nr 23, failed to react with either 
the chromosome 17 or the p53 probe, thus the results of this sample were not 
included. Significant p53 amplification was not observed in any of the remaining 
24 samples as only a few nuclei in a small number of samples (8) had 3 or more 
signals. 
Eleven (46%) of the 24 samples showed nuclei with no signals for p53, 23 (96%) 
samples showed nuclei with one signal, 23 (96%) samples showed nuclei with 
two signals and 8 (35%) samples showed nuclei with 3 signals. None of the 
samples showed the presence of more than three signals per nucleus. Figure 4.1 
shows representative photographs of p53 hybridisation. 
Eighteen of the samples showed an LOA rate of <9%, meaning no significant loss 
of p53. Six of the samples displayed an LOA of >9%: samples 4,7,8, 10, 12 
and 24 showed an LOA of 44%,29%, 10%, 10%,56% and 100% respectively. 
Samples 4, 7, 8, 10 and 12 (peripheral blood) were in CP, whereas sample 24 
was in AP (bone marrow). For samples 4, 7, 8, 10 and 12 the Ph chromosome 
studies were positive, whereas in sample 24 the Ph chromosome was negative. 
For samples 4, 7, 12 the BCRlABL PCR was not performed, and the BCRlABL 
PCR of samples 8, 10 and 24 were negative. It must be noted that samples 8 
and 10 were those of the same patient sent in at different times. Twelve of the 
Nucleus with 2 signals for 
chromosome 17 (green) and 2 
signals for p53 (orange) 
Nucleus with 1 signal for 
chromosome 17 (green) and 2 
signals for p53 (orange) 
Nucleus with 2 signals for 
chromosome 17 (green) and 1 
signal for p53 (orange) 
Nucleus with 1 signal for 
chromosome 17 (green) and 1 
signal for p53 (orange) 
Nuclei that failed to react with 
either probe 
Figure 4.1 Representative photographs of p53 hybridisation 
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samples showed no LOA. Sample 11 in BP showed an LOA of only 2%, and 
samples 14 and 22 in AP showed no LOA, whereas sample 24 in AP showed an 
LOA of 100%. Sample 17, which transformed to ALL, showed no LOA. 
For chromosome 17 copy numbers, 24 (100%) of the samples showed one 
signal, 24 (100%) samples showed two signals and 1 (4%) sample showed 3 
signals for p53. None of the samples showed more than 3 copies. Table 4.1 
shows the relationship between number of signals for chromosome 17 and p53 in 
the samples by FISH. 
No significant p53 amplification or deletion was detected in any of the 900 control 
nuclei counted to assess hybridisation efficiency (Table 4.2). Twenty-nine (3%) 
of the 900 nuclei counted showed 1 signal for p53, 862 (96%) showed 2 signals 
and 9 (1 %) showed 3 signals. None of the control nuclei counted showed more 
than 3 signals for p53. No extra copy numbers for chromosome 17 were counted 
in any of the 900 control nuclei. Thirteen (1 %) of the 900 nuclei counted showed 
1 signal and 887 (99%) showed two signals for chromosome 17. 
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Sample Clinical Ph p53 p53 Chromosome 17 
number course status number of nuclei with th is number of signals % LOA number of nuclei w ith this number of 
signals 
0 1 2 3 >3 0 1 2 3 >3 
1 CP + 6 31 62 1 0 6 0 29 71 0 0 
2 CP NC 0 25 75 0 0 0 0 27 73 0 0 
3 CP + 0 52 48 0 0 0 0 48 52 0 0 
4 CP + 44 48 8 0 0 44 0 76 24 0 0 
5 CP + 0 46 54 0 0 0 0 49 51 0 0 
6 CP + 2 55 42 1 0 2 0 56 44 0 0 
7 CP + 29 49 22 0 0 29 0 61 39 0 0 
8 CP + 10 49 41 0 0 10 0 40 59 1 0 
9 CP + 0 44 56 0 0 0 0 41 59 0 0 
10 CP + 10 49 41 0 0 10 0 42 58 0 0 
11 BP + 2 81 16 1 0 2 0 64 36 0 0 
12 CP + 56 38 6 0 0 56 0 52 48 0 0 
13 CP + 8 30 60 2 0 8 0 36 64 0 0 
14 AP + 0 10 89 1 0 0 0 8 91 0 0 
15 CP + 0 20 79 1 0 0 0 20 80 0 0 
16 CP + 0 29 71 0 0 0 0 18 82 0 0 
17 T/ALL + 0 2 98 0 0 0 0 1 99 0 0 
18 CP + 0 24 76 0 0 0 0 2 98 0 0 
19 CP + 6 3 91 0 0 6 0 35 65 0 0 
20 CP + 0 13 86 1 0 0 0 9 91 0 0 
21 CP + 2 12 85 1 0 2 0 5 95 0 0 
22 AP + 0 1 99 0 0 0 0 1 99 0 0 
23 TlMyel NP 0 0 0 0 0 NC 0 0 0 0 0 
24 AP - 100 0 0 0 0 100 0 2 98 0 0 
25 CP + 0 7 93 0 0 0 0 8 92 0 0 
Nrs. 1-21 : peripheral blood; Nrs. 22-25: bone marrow; NC: non-conclusive; NP: not-performed 
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Table 4.2 Relationship betw -~ .. .. _ ... ber of sianals for ch ._ ... _-_ ... - 17 and p53 In 900 - - - .. _ .. .. _. _. Ipheral blood leukocvt, 
--
Count per p53 Chromosome 17 
100 nuclei 
#of # of # of #of #of #of # of #of # of # of 
nuclei nuclei nuclei nuclei nuclei nuclei nuclei nuclei nuclei nuclei 
with 0 with 1 with 2 with 3 with >3 with 0 with 1 with 2 with 3 with >3 
siqnals siqnal siqnals siqnals siqnals siqnals siqnal siqnals siqnals siqnals 
1 0 2 97 1 0 0 1 99 0 0 
2 0 3 95 2 0 0 3 97 0 0 
3 0 5 93 2 0 0 2 98 0 0 
4 0 3 97 0 0 0 1 99 0 0 
5 0 4 95 1 0 0 4 96 0 0 
6 0 4 95 1 0 0 1 99 0 0 
7 0 3 95 2 0 0 0 100 0 0 
8 0 2 98 0 0 0 0 100 0 0 
9 0 3 97 0 0 0 1 99 0 0 
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Cyclin 01 signals were counted for 100 interphase nuclei per sample slide. 
Staining quality assurance controls, consisting of a normal peripheral blood 
sample, were included for each probe set. Since there were nuclei that fai led to 
react with the probes, cells were scored only when at least one bright orange 
Signal for cyclin 01 and/or one bright green signal for chromosome 11 was 
present. The total number of cells (per sample) with hybridisation signals for 
cyclin 01 was compared to the total number of cells with signals for chromosome 
11 in order to determine the presence of amplification or deletion. LSI cyclin 01 
SO / CEP 11 SG dual colour DNA probe hybridised to band 11 q13, and to the 
centromere, band region 11 p11 .11 -q11 , locus 011Z1 of human chromosome 11 , 
respectively. 
The criteria for cyclin 01 gene amplification in interphase nuclei and metaphase 
chromosomes are not well established in the literature, nor is there consensus as 
to what should be called amplification. The definition of gene amplification is thus 
more or less subjective. In this instance amplification was defined as more than 
two foci of cyclin 01 hybridisation per nucleus (Sheyn et al., 1997; Suzuki et a/. , 
1998; Hoechtlen-Vollmar et a/. , 2000). The significance of LOA for cyclin 01 
could not be established from the literature. 
Cyclin 01 amplification was not observed in any of the 25 CML samples 
examined. Thirteen (52%) of the 25 samples showed the presence of nuclei with 
no signals, 23 samples (92%) showed nuclei with one signal and all 25 (100%) 
samples showed the presence of nuclei with two signals. NoneTo ~ ~ m'1~ IS )TttE PRO ERTY 
showed the presence of more than two signals for cyclin 01 p r nucle~S: "Figure 
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4.2 shows representative photographs of cyclin 01 hybridisation. However, 
although no amplification was detected, LOA for cyclin 01 was detected in 13 of 
the 25 samples. Samples 14, 22 and 24 in AP showed an LOA of 0%,75% and 
96% respectively. Sample 11 in BP showed an LOA of 45%, sample 17 which 
transformed to ALL showed a 2% LOA and sample 23 which transformed to 
myelofibrosis showed an LOA of 0%. The percentage LOA between samples in 
CP varied from 0-61 %. 
No extra copies of chromosome 11 were found in any of the samples. One 
sample (4%) showed the absence of chromosome 11 in 30% of the nuclei 
counted, 24 (96%) samples showed one signal for chromosome 11 and 25 
(100%) samples showed the presence of 2 signals for chromosome 11. Table 
4.3 shows the relationship between the number of signals for chromosome 11 
and cyclin 01 in the samples by FISH. 
Amplification of cyclin 01 was not detected in any of the 900 control nuclei 
counted to assess hybridisation efficiency (Table 4.4). Thirty-four (4%) of the 900 
nuclei counted showed 1 signal , 859 (95%) showed 2 signals and 7 (1 %) showed 
3 Signals. No significant amplification or deletion of chromosome 11 copy 
numbers was detected. In the 900 control nuclei counted, 6 (1 %) nuclei showed 
3 signals for chromosome 11 , 57 (6%) nuclei showed one signal, and 837 (93%) 
nuclei showed two signals. 
Nucleus with 2 signals for 
chromosome 11 (green) and 2 
signals for cyclin 01 (orange) 
Nucleus with 1 signal for 
chromosome 11 (green) and 2 
signals for cyclin 01 (orange) 
Nucleus with 2 signals for 
chromosome 11 (green) and 1 
signal for cyclin 01 (orange) 
Nucleus with 1 signal for 
chromosome 11 (green) and 1 
signal for cyclin 01 (orange) 
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Nucleus that failed to react with 
either probe 
Figure 4.2 Representative photographs of cyclin 01 hybridisation 
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Sample Clinical Ph 
number course status 
1 CP + 
2 CP NC 
3 CP + 
4 CP + 
5 CP + 
6 CP + 
7 CP + 
8 CP + 
9 CP + 
10 CP + 
11 BP + 
12 CP + 
13 CP + 
14 AP + 
15 CP + 
16 CP + 
17 T/ALL + 
18 CP + 
19 CP + 
20 CP + 
21 CP + 
22 AP + 
23 T/Myel NP 
24 AP 
-
25 CP + 
Nrs. 1-21: peripheral blood 
Nrs . 22-25: bone marrow 
NC: non-conclusive 
NP: not-performed 
Cyclin 01 Cyclin 
number of nuclei with this number of signals 01 
0 1 2 3 >3 % LOA 
a 23 77 a a a 
a 15 85 a a a 
11 26 62 a a 11 
26 38 36 a a 26 
8 25 66 a a 8 
2 25 73 a a 2 
16 38 46 a a 16 
a 5 95 a a a 
4 47 49 a a 4 
3 20 77 a a 3 
45 40 14 a a 45 
61 34 5 a a 61 
8 27 65 a a 8 
a a 100 a a a 
a 15 85 a a a 
a 22 78 a a a 
2 10 88 a a 2 
a 41 59 a a a 
a 1 99 a a a 
a a 100 a a a 
a 2 98 a a a 
75 4 21 a a 75 
a 7 93 a a a 
96 1 3 a a 96 
a 16 84 a a a 
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Chromosome 11 
number of nuclei with this number of signals 
0 1 2 3 >3 
a 28 72 a a 
a 15 85 a a 
a 28 72 a a 
30 50 20 a a 
a 26 74 a a 
a 27 73 a a 
a 45 55 a a 
a 5 95 a a 
a 54 46 a a 
a 19 81 a a 
a 72 28 a a 
a 65 35 a a 
a 38 62 a a 
a 5 95 a a 
a 15 85 a a 
a 23 77 a a 
a 10 90 a a 
a 46 54 a a 
a 3 97 a a 
a a 100 a a 
a 1 99 a a 
a 1 99 a a 
a 7 93 a a 
a 9 91 a a 
a 14 86 a a 
.-
-
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Table 4.4 Relationship between number of signals for chromosome 11 and cyclin 01 in 900 normal 
. heral blood leukocvt, peripi 
--
Count per Cyclin Dl Chromosome 11 
100 nuclei 
# of #of #of #of #of # of #of #of #of #of 
nuclei nuclei nuclei nuclei nuclei nuclei nuclei nuclei nuclei nuclei 
with 0 with 1 with 2 with 3 with >3 with 0 with 1 with 2 with 3 with >3 
siqnals siqnal siqnals siqnals sionals sionais sionai sionais sionals sionals 
1 0 7 92 1 0 0 5 95 0 0 
2 0 4 96 0 0 0 8 90 2 0 
3 0 4 96 0 0 0 4 96 0 0 
4 0 3 97 0 0 0 3 97 0 0 
5 0 1 99 0 0 0 3 95 2 0 
6 0 7 91 2 0 0 9 91 0 0 
7 0 2 96 2 0 0 7 92 1 0 
8 0 1 98 1 0 0 9 91 0 0 
-- ~ - -- 0 __ _ 5 ___ 94 1 "----- 0 _ _ _ 0_ 9 
- -
90 1 0 
- - - --- --
- - _ ... _- ----
-- -
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COMPARATIVE 
In general, the patient group studied here showed more abnormality for chromosome 
17/p53 than for chromosome 11/cyclin 01. In the 6 samples that showed LOA >9% 
for p53, cyclin 01 LOA was observed in five of the six samples, whereas samples 4, 
7, 8,1 0, 12 and 24 showed cyclin 01 deletion in 26%,16%, 0%, 3%, 61% and 96% 
of the nuclei respectively (Table 4.5). In samples 3, 5, 6, 9, 10, 11 , 13, 17 and 22 
where cyclin 01 LOA was observed, only sample 10 showed a significant p53 LOA of 
10%. In samples 4, 7, 12, and 24, high percentages of LOA were detected both for 
p53 and cyclin 01. Sample 23 that failed to react with the p53 and chromosome 17 
probes, did however react with cycl in 01 , but no amplification or deletion was 
detected for cyclin 01 . It must be noted that in sample four, 30% of the nuclei failed 
to react with the probe for chromosome 11 , whereas 26% of nuclei fai led to react with 
the probe for cyclin 01 . 
One would expect a correlation between chromosome abnormality and disease 
stage. In this study, however, the correlation is not that clear. Nineteen of the 
samples are in CP and samples 11 , 14, 17, 22, 23 and 24 are in advanced stages of 
the disease, yet their results do not reflect this. This clearly shows that other genes 
are involved as well and that the progression of this disease is very complex. 
Table 4.5 C r 01 omparlson of %LOA between p53 and eye In 
Sample number Clinical course 
1 CP 
2 CP 
3 CP 
4 CP 
5 CP 
6 CP 
7 CP 
8 CP 
9 CP 
10 CP 
11 BP 
12 CP 
13 CP 
14 AP 
15 CP 
16 CP 
17 T/ALL 
18 CP 
19 CP 
20 CP 
21 CP 
22 AP 
23 T/Myel 
24 AP 
25 CP 
Nrs 1-21 : peripheral blood 
Nrs 22-25: bone marrow 
NC: non-conclusive 
NP: not-performed 
Ph status P53: 
+ 
NC 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
NP 
-
+ 
71 
% LOA Cyclin 01: % LOA 
6 0 
0 0 
0 11 
44 26 
0 8 
2 2 
29 16 
10 0 
0 4 
10 3 
2 45 
56 61 
8 8 
0 0 
0 0 
0 0 
0 2 
0 0 
6 0 
0 0 
2 0 
0 75 
NC 0 
100 96 
0 0 
I'L 
CHAPTER 5 
DISCUSSION 
Despite the multitude of studies on p53, there are considerable differences in the 
methods of detection and interpretation criteria. A major problem in drawing 
conclusions from this study, is the difficulty in comparing malignant cells from the 
different clinical courses, due to the uneven distribution of the different population 
sizes and the fact that no control cell lines were used. However, comparative 
deletion studies between control cell lines and leukaemic patient cells are a 
problem because it is difficult to obtain control cell line samples as normal 
counterparts of leukaemic cells. Sugimoto et al. (1992) suggested that mutation 
or inactivation of the p53 gene, unlike in fresh myeloid leukaemia cells, is 
common in myeloid leukaemia cell lines because loss of normal function of this 
gene helps them acquire long-term proliferation potential in vitro. Because cell 
lines are frequently used in experimental studies as prototype malignant cells that 
grow in vivo, it is important to know whether abnormalities in critical cancer-
associated genes, such as p53 observed in cancer cell lines, indeed reflect the 
lesion present in the original malignant cells growing in vivo (Sen et ai, 1995) . 
. 
p53 LOA >9% was detected in 5 chronic phase samples (Ph' I peripheral blood) 
and in one accelerated phase sample (Ph- I bone marrow). The absence of the 
Ph chromosome (sample 24) is a major poor-prognosis feature translating into a 
median survival time of 9 to 14 months compared with 3 to 4 years for Ph 
chromosome positive disease (Gomez et aI., 1981). p53 deletions andlor 
I'J 
mutations have been described in 10-25% of the cases of CML, especially those 
with a myeloid phenotype, but were rare during the chronic phase (5%) (Imamura 
et aI. , 1994). No LOA >9% was detected in any of the other samples despite the 
clinical course. The results of this study correlate with those done by Stuppia et 
aI., (1997) who showed a significant LOA >15% in 3 out of 12 (25%) patients in 
chronic phase and an LOA <15% in 5 out of 13 (39%) patients in blastic phase. 
Eight out of 13 patients did, however, show an LOA of >15% in BP. It is thus 
possible that the samples in the present study that showed LOA >9%, was 
analysed during a late chronic phase, just preceding blastic crisis, indicating that 
p53 tumour suppressor genes may be involved in the progression of 6 out of 24 
cases of CML. Several investigators have shown that loss of the normal function 
of p53 plays a significant role in the malignant transformation process. 
Inactivation of functional alterations of both alleles of the gene through deletions, 
insertions and point mutations have been shown in various types of human 
malignancies, including those of haematopoietic origin (Honda et aI., 2000; 
Stuppia et aI., 1997). Among myeloid leukaemia cells, although gross structural 
alterations and point mutations have both been reported, their frequency remains 
a subject of controversy (Kelman et aI., 1989). 
Changes in the p53 gene may also be involved in the rare megakaryocytic blast 
crisis variant, but evidence was against its involvement in lymphoid blastic 
transformation of in Ph+ ALL (Ahuja et al. 1991). In studies done by Stuppia et 
a/. , (1997) 5 out of 13 patients without a significant LOA rate had a lymphoid BC, 
and showed a persistence of apoptotic processes although at a lower rate than 
compared to CPo p53 rearrangements and the related suppression of apoptosis 
14 
seem to be specifically associated with a myeloid evolution of the disease. This 
would explain the results of sample 17 which transformed to ALL and where no 
apparent deletion or amplification was detected. Molecular events other than 
those involving the p53 gene are thus likely to be responsible for the 
transformation of CML to Ph+ ALL. Since CML evolution occurs toward two 
distinct forms, namely a myeloid or a lymphoid acute phase, different genetic 
alterations might thus lead to the distinct blast crisis phenotypes (Iolascon et aI. , 
1998) 
In the present study, factors such as therapy, disease evolution, possible 
transplants and survival were not taken into consideration, nor was any analysis 
done to determine mutations of p53 or the possible actions of cytokines. Another 
important point is the relationship between the p53 rearrangement and the 
phenotype of the blastic phase. A larger group of samples studied in a 
prospective manner during the duration of disease progress from time of 
diagnosis to fatal blast crisis, will better clarify these issues. FISH with 
chromosome- and/or locus-specific DNA probes allows one to obtain cytogenetic 
information from interphase cells and is a powerful tool for monitoring the 
expansion of the leukaemic clone with p53 LOA Furthermore, by using FISH, it 
was easy to determine whether a locus is lost. It would be advisable, however, 
that in the instance where bone marrow examples are examined, the samples be 
, 
collected in a heparinised syringe and that the mononuclear bone marrow cells 
be separated by density gradient centrifugation over Ficoll-Hypaque (Drach et aI., 
1998; Sankar et aI. , 1998). Using this method one can more readily control the 
distribution of the cells on the slides, avoiding overlapping and layering of cells, 
,:> 
and eliminating unnecessary background material, which causes technical 
difficulty when scoring the results. 
Isochromosome 17q (i(17q)) is the most common isochromosome in 
haematologic malignancies and has been described as a primary and a 
secondary aberration. i(17q) is a frequent secondary chromosomal aberration in 
the accelerated phase or blast crisis of CML, indicating that this abnormality also 
plays an important role in disease progression (Mitelman, 1993). As a 
consequence of the i(17q) formation, one copy of this gene will be lost, an event 
that could unmask the effects of an existing mutation in the other allele. Given 
the frequent occurrence of i(17q) in haematologic malignancies, and the fact that 
i(17q) is sometimes found as the sole karyotypic abnormality, suggesting a 
possible role as a primary genetic alteration in leukemogenesis, Fioretos et al. 
(1999) studied its role in haematologic neoplasms by FISH. Because i(17q) 
formation results in loss of 17p material, potentially unmasking the effect of a 
tumour suppressor gene, they also studied the occurrence of p53 mutations by 
sequencing the entire coding region. No coding p53 mutations were identified in 
any of the cases investigated, hence the formation of an i(17q) does not serve to 
uncover the effect of an already existing p53 mutation in the normal appearing 
chromosome 17. They also did not detect any clear-cut differences between the 
localization of the chromos?mal breakpoints and the type of haematologic 
malignancy in their studies, suggesting that 17p harbours a "promiscuous" gene 
which, if structurally rearranged or otherwise deregulated, is pathogenetically 
important in a wide variety of neoplasms (Fioretos et a/. , 1999). In this study the 
presence of i(17q) was not detected by interphase FISH, so it may be present but 
(0 
undetected. By using dual colour FISH with specific probes for the centromeric 
region of chromosome 17 and for the p53 gene, it is, however, possible to 
determine simultaneously the number of chromosome 17 and detect regional loss 
of 17p13 in metaphase chromosomes. It is a simple method, requiring very little 
material (Kobayashi et aI., 1996). 
The high sensitivity of FISH was also exploited by Sankar et al. (1998) to detect 
the loss of various loci on 17p13, among others p53 (17p13.1), cC117-732 
(17p13.1) 017S34 (17p13.1) , 017S379 (17p13.3) and cCI17-636 (17p13.2). 
Their results indicated that FISH was accurate and a relatively easy method, and 
technical errors occurring during PCR can be avoided. FISH is therefore an 
appropriate method for performing deletion mapping in leukaemia patients. 
Furthermore, their results suggested that there may be new oncogenes located 
on the commonly deleted region (17p) that may have an important role in the 
progression of leukaemia (Sankar et aI., 1998). Loss of p53 hybridisation signals 
is predominantly due to an interstitial deletion that is presumably to small to be 
detected on metaphase chromosomes, thus increasing the evidence that FISH is 
a more sensitive method than banding analysis to detect deletions of narrow 
chromosomal regions (Drach et aI. , 1998). 
Cyclin 01 amplification by FISH was not detected in any of the peripheral blood 
samples or the bone marrows. These results are in concurrence with those found 
by other researchers, albeit by other methods. The expression of the three types 
of O-cyclins that have been identified, is tissue and cell-type specific. Cyclin 01 
is mainly expressed by epithelial and mesenchymal cells, but not in cells of 
/I 
lymphoid and myeloid lineages, whereas cyclins 02 and 03 are expressed by 
myelomonocytic and lymphoid cells (Sonoki et aI. , 1999; Ott et aI. , 1997). Della 
Ragione et a/. (1997) analyzed the G, phase proteic machinery, including cyclin 
o types, COKs and COK inhibitors, of cell populations obtained at different stages 
of haematopoietic cell lineage. Five cellular phenotypes were studied as 
representatives of distinct differentiation pathways. Their results indicated that al 
the cellular preparations express cyclin 02 and 03, but not cyclin 01 . 
Ajchenbaum et a/ (1993) observed the induction of cyclin 02 and 03, but not 
cyclin 0 1, in normal murine T cells. In studies with 24 different transformed 
human haematopoietic cell lines, cyclin 03 was found to be expressed in both 
myeloid and lymphoid cell lines, whereas cyclin 02 was expressed in a small 
fraction, without regard to whether the line was myeloid, T cell or B cell in origin. 
The significance of cyclin 01 in human myeloproliferative disease needs 
clarification since cyclin 01 , which is the major cyclin 0 occurring in 
mesenchymal tissues, is not normally expressed in human haematopoietic cells, 
and mice with cyclin 01 knock-outs do not have clear defects in haematopoiesis 
(Della Ragione et aI. , 1997; Ajchenbaum et aI. , 1993; Sicinski et aI. , 1995). 
Cyclins 02 and 03 are, however, expressed in human haematopoietic cells and 
are good candidates as BCRlABL target molecules (Gesbert et aI. , 2000). 
The 11 q13 region of chromosome 1 f is amplified in several types of human 
carcinoma and harbours several genes that could playa role in tumourigenesis, 
including the proto-oncogenes INT2, HST1 and EMS1 (Lammie and Peters, 
1991). Since the amplicon is quite extensive, these other candidate oncogenes 
could be co-amplified. The role of these genes on the 11 q13 region was not 
/Il 
investigated in this study, thus their role in tumourigenesis of CML was not 
established. 
In the present study the 11 q13 amplification of cyclin D1 in peripheral blood cells 
and bone marrow from patients, with various stages of CML, were investigated. 
Although this assay assesses only chromosome 11 and cyclin D1 , the ease and 
convenience of this method are very attractive. Although no amplification was 
observed in this study, FISH was demonstrated by others to be a suitable method 
for the detection of 11 q13 amplification in squamous cell carcinoma of the head 
and neck, esophageal squamous cell carcinomas, mantle cell lymphomas, and 
ovarian carcinomas, (Alavi et al., 1999; Sheyn et aI. , 1997; Katz et al., 2000; 
Diebold et al., 2000). FISH allows for the precise localization of the amplified 
gene within the cells and it allows the detection interphase chromosomal 
rearrangements using non radio-active probes (Sheyn et aI. , 1997; Devilee et aI. , 
1988). Furthermore, FISH does not require ~urified DNA and results are thus not 
affected by degradation. Multicoloured probes can be used simultaneously, 
thereby increasing the significance of the observation, and results are available in 
24 hours (Alavi et aI., 1999). Dual labelling and hybridisation with multiple probes 
allows localization of the gene to its specific chromosome. It was also shown that 
FISH analysis can be readily applied to formalin-fixed, paraffin-embedded 
tissues. FISH analysis is therefore well suited for use in studies using archival 
tissues (Sheyn et al., 1997). However, a drawback of this method is that the 
probe which is specific for the 11 q13 breakpoint, may not be useful for detecting 
the t(11;1 4)(q13;q32) chromosomal translocation, and, in addition, the 11q13 
{>J 
locus may be translocated with sites other than 14q32, resulting in a fusion 
product that is not the 1 (11; 14) (Katz et aI., 2000). 
Similar negative amplification results have been reported in anal carcinomas, and 
it was suggested that cyclin 01 alterations do not play a significant role in 
tumourigenesis in the anal region (Sheyn et aI., 1997). Katz et aI., (2000) also 
showed that 8-cell non-Hodgkin lymphomas rarely have a substantial number of 
cells with more than two 11 q13 signals. Immunohistochemical examination of 
cases of AML, ALL, T-cell ALL and MOS also showed no cyclin 01 expression, 
suggesting that cyclin 01 might not be involved in the pathogenesis of the 
leukaemia despite the cytogenetic involvement of 11q13 (Wong, 1999). The 
involvement of 11 q13 in a diversity of chromosomal rearrangements in myeloid 
and lymphoid neoplasia is intriguing. There is a possibility of a variety of 
breakpoint involvement in 11 q13 abnormalities which are indistinguishable at 
microscopic level. On the other hand, the underlying molecular changes may be 
similar, despite the fact that different chromosomes are involved in 
rearrangement with 11 q13, as in the case of 11 q23 (Kwong et a/., 1995). Clearly, 
further molecular studies are required to clarify this issue. 
The results of this study require a re-examination of the involvement of cyclin 01 
in leukocyte proliferation as it did not endorse the diagnostic value of cyclin 01 
amplification. Cyclin 01 over-expression, as a result of amplifications and/or re-
arrangements, is an important contributing factor to oncogenesis although its 
pathological significance in CML is still unclear. However, the high expression of 
cyclin 01 in certain myeloid leukaemias was identified to reflect their proliferative 
80 
activity and not to represent the oncogenic over-expression (Suzuki et aI., 2001). 
Because cyclin D1 expression is not seen in normal haematopoietic cells, the 
expression of cyclin D1 in lymphomas other than MCl may also indicate that 
cyclin D1 is an ubiquitous oncogene (Aguilera et aI., 1998). The functional role of 
STAT5 and cyclin D1 in haematopoiesis might be redundant and replaced 
sufficiently by other signalling molecules and other D-type cyclins (Matsumura et 
aI., 1999). Thus, analysis of normal counterparts for regulation of the D-type 
cyclins, especially cyclin D2 and D3, is needed to understand the significance of 
the apparent promiscuous usage of D-type cyclins in haematopoietic cells. 
In this study no correlation could be made between p53 lOA and over-expression 
of cyclin D1 in the various stages of CML. It was, however, demonstrated in 
studies by Opitz et aI., (2001) that over-expression of cyclin D1 and p53 
inactivation led to the immortalization of oral keratinocytes. It was also shown 
than cyclin D1 protein accumulates to significantly higher levels in murine 
fibroblasts in which wild-type p53 is induced, and it provided evidence that 
increased cyclin D1 protein appears necessary, in concert with waf1/p21 , for the 
induction of a proper G1 arrest as mediated by wild-type p53 (Del Sal et aI., 
1996). 
Despite all the information on CMl, one can only quote Deininger et al. (2000) in 
asking: "Why is there a predominantly myeloid expansion when all 3 lineages 
carry the BCRlABl translocation? What is the biologic basis for the extraordinary 
variability in the clinical course of a disease that appears to carry just a single 
genetic lesion? What is the molecular basis for the genomic instability that we 
81 
see clinically as relentless progression to blast crisis?" It is clear that cellular 
processes rely on integrated networks and not on unidirectional pathways. Only 
in this way can the cell achieve the flexibility required to respond to the various 
stimuli within a multicellular organism. To understand the extraordinary 
complexity of CML, it is therefore necessary to undertake the demanding task of 
studying signal transduction in primary progenitor cells. 
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